Laura Bukavina, Urologic Oncologist at Cleveland Clinic Urology, shared a post on X:
“When control patients drop out for better options, outcomes get skewed equals perceived inferiority bias
In Bladder Cancer trials this bias inflated PFS/OS for chemo + IO. Adjustments erased OS (nivolumab, CheckMate901) and PFS (pembrolizumab, KEYNOTE-361). RCT are not perfect.”
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring
Authors: Tomer Meirson, Jonathan Ofer, Noa Zimhony-Nissim, Avital Bareket-Samish, Gal Markel, Victoria Neiman, Nathan Cherny, Daniel A. Goldstein, Bishal Gyawali, Ian Tannock, Eli Rosenbaum.
